News

Home>News
News2020-07-17T11:41:26-04:00
Dec 102020

Halberd Corporation Discusses Positive Antibody Test Results Against COVID-19 with The Stock Day Podcast

December 10th, 2020|Categories: Featured, Investor News, News|Tags: , , , , , , |

Phoenix, December 10th, 2020 (Newsfile Corp.) -- The Stock Day Podcast welcomed Halberd Corporation (HALB) (“the Company”), a company with a patented extracorporeal treatment applicable to many hard-to-cure blood-borne and neurological diseases, including Covid-19, other viruses, and PTSD. President and CEO of the Company, William A. Hartman, joined Stock Day host Everett Jolly. Jolly began the interview by asking about the Company’s recent press release detailing promising SARS-CoV-2 laboratory testing. “Our primary technology is our ...

Dec 72020

Halberd Corp. Research Yields Promising SARS-CoV-2 Antibody in Laboratory Testing

December 7th, 2020|Categories: Featured, Investor News, News|Tags: , , , , , , |

Jackson Center, PA, December 7, 2020 – Halberd Corporation (OTC PINK: "HALB") announced the promising results of laboratory testing on their new patent pending SARS-COV-2 monoclonal antibody generated through their university research.  The antibody testing to date has shown extremely potent action against the SARS-CoV-2 spike protein.  Scientific details of the testing to date will be released later this week. William Hartman, the CEO and President of commented, “Within the next two days we will ...

Dec 22020

Halberd Corporation’s Covid-19 Technology Recognized by Momentum Observer

December 2nd, 2020|Categories: Featured, Investor News, News|Tags: , , , , , , , , , , |

Jackson Center, PA, December 2, 2020 – Halberd Corp. (OTC PINK: "HALB") was recently included in a Momentum Observer article on Covid-19 along with big pharma companies Pfizer (PFE: NYSE), Moderna (MRNA: NASDAQ), BioNTech (BNTX: NASDAQ) and AstraZeneca (AZN: NASDAQ).  The article featured Halberd's nasal spray currently under development that could be an effective alternative to a vaccine against Covid-19. William A. Hartman, Chairman, President and CEO of Halberd Corporation, stated, “Halberd is also working ...

Dec 12020

Halberd Corporation Advisory Board Reorganization Announced

December 1st, 2020|Categories: Featured, Investor News, News|Tags: , , , , , |

Jackson Center, PA, December 1, 2020 – Halberd Corp. (OTC PINK: "HALB") announces the reorganization of its Scientific Advisory Board.  The new Advisory Board will consist of two sub-boards: a multi-disciplined Scientific Advisory Board focused on biomedical issues and a Business Advisory Board focusing on business issues.  The two boards will interface on a regular basis in order to strike the proper balance between science and business needs. The Halberd Scientific Advisory Board members include: ...

Nov 252020

Halberd Corp. CEO Interviewed on Money TV;
Discusses 2020 Accomplishments and Plans

November 25th, 2020|Categories: Featured, Investor News, News|Tags: , , , , , , , |

Jackson Center, PA, November 25, 2020 – Halberd Corporation (OTC-PINK: "HALB") Chairman, President and CEO, William A. Hartman, was interviewed this week by host, Donald Baillargeon, on Money TV.  Mr. Hartman recapped the company’s accomplishments, describing its most promising technologies and described the unique applications perceived, including a sneak peek at the future. Mr. Hartman detailed some of the most recent developments in Halberd’s top priority research: to develop products which should facilitate diagnostic, prevention ...

Nov 192020

Halberd Corporation Files for Patent Protection on Covid-19 Extracorporeal Treatment Variation

November 19th, 2020|Categories: Featured, Investor News, News|Tags: , , , , , , |

Jackson Center, PA, November 19, 2020 – Halberd Corp. (OTC PINK: "HALB") reported the filing of a provisional patent application on a variation of Halberd’s patented extracorporeal method to treat/eradicate Covid-19 from a patient’s blood.  By using an extracorporeal (outside the body) treatment method, the patient is exposed to far fewer potential negative side effects than with more conventional treatment regimens. Halberd’s provisional patent application, “Method For Treating And Curing Covid-19 Infection By Utilizing Radio ...

Go to Top